1. Home
  2. LODE vs NYXH Comparison

LODE vs NYXH Comparison

Compare LODE & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Comstock Inc.

LODE

Comstock Inc.

N/A

Current Price

$3.48

Market Cap

167.1M

Sector

Industrials

ML Signal

N/A

Logo Nyxoah SA

NYXH

Nyxoah SA

N/A

Current Price

$4.78

Market Cap

188.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LODE
NYXH
Founded
2008
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Major Chemicals
Medical/Dental Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
167.1M
188.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
LODE
NYXH
Price
$3.48
$4.78
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
$4.00
$12.67
AVG Volume (30 Days)
828.9K
48.0K
Earning Date
10-30-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,778,445.00
$6,616,215.00
Revenue This Year
N/A
$79.25
Revenue Next Year
$1,798.62
$297.08
P/E Ratio
N/A
N/A
Revenue Growth
48.99
10.96
52 Week Low
$1.67
$4.35
52 Week High
$10.10
$11.87

Technical Indicators

Market Signals
Indicator
LODE
NYXH
Relative Strength Index (RSI) 53.34 44.65
Support Level $3.19 $4.69
Resistance Level $3.70 $4.90
Average True Range (ATR) 0.26 0.20
MACD -0.00 0.02
Stochastic Oscillator 54.03 41.18

Price Performance

Historical Comparison
LODE
NYXH

About LODE Comstock Inc.

Comstock Inc innovates and commercializes technologies that are deployable across entire industries to contribute to energy abundance by efficiently extracting and converting under-utilized natural resources, such as waste and other forms of woody biomass into renewable fuels, and end-of-life electronics into recovered electrification metals. Comstock's innovations group is engaged in developing and using artificial intelligence technologies for advanced materials development.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: